
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded slow release capsule containing verapamil hydrochloride, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
FDA-approved products containing verapamil are listed in capsule, tablet and injection forms.
This is a solid, nonaqueous dose form. Under USP <795>, nonaqueous preparations carry longer default beyond-use dates than water-containing ones. The date printed on the label is the one to follow.
Compounded drugs are not FDA-approved. This means that FDA does not review these drugs to evaluate their safety, effectiveness, or quality before they reach patients.
Verapamil is a calcium channel blocker that compounding pharmacies prepare as topical and transdermal gels, sterile intralesional injections and oral liquids by prescription.
Verapamil is a phenylalkylamine calcium channel blocker. It slows the flow of calcium into heart muscle and the smooth muscle of blood vessels, which relaxes arteries, lowers the heart's workload and slows electrical conduction through the AV node. Manufactured products include immediate-release tablets (generic; the Calan brand is discontinued), extended-release tablets and capsules (Isoptin SR, Verelan and generics) and an intravenous injection. The tablets are FDA-approved for angina (vasospastic, unstable and chronic stable), ventricular rate control in chronic atrial fibrillation or flutter with digitalis, prophylaxis of repetitive paroxysmal supraventricular tachycardia, and hypertension. Laboratory work has also shown that verapamil reduces collagen secretion by fibroblasts. A prescriber might order compounded verapamil as a topical gel, a sterile preparation for local injection, or an oral liquid for a patient who cannot swallow tablets. Compounded preparations are not FDA-approved and require a prescription.
Verapamil carries no boxed warning. Oral verapamil must not be used in severe left ventricular failure, very low blood pressure or cardiogenic shock, sick sinus syndrome or advanced heart block without a pacemaker, atrial fibrillation with an accessory bypass tract, or known allergy. It can worsen heart failure, lower blood pressure, slow the heart, raise liver enzymes, and worsen myasthenia gravis or muscular dystrophy. A beta blocker adds to these effects; verapamil raises digoxin, lithium, simvastatin, lovastatin, cyclosporine, carbamazepine and theophylline levels. The label says it crosses the placenta, should be used in pregnancy only if clearly needed, and advises against nursing; Drugs.com's breastfeeding monograph, citing primary studies, reports low milk levels and no problems in older breastfed infants. Call your prescriber for fainting, a very slow pulse, shortness of breath, or yellowing skin or eyes. If side effects bother you, talk to your prescriber or pharmacist.
Verapamil inhibits transmembrane calcium influx in cardiac and vascular smooth muscle, reducing afterload and myocardial oxygen demand, relieving coronary spasm and slowing AV nodal conduction without bronchoconstriction. Oral absorption exceeds 90 percent but first-pass metabolism leaves bioavailability at 20 to 35 percent; peak levels occur at 1 to 2 hours; protein binding is about 90 percent; elimination half-life is 2.8 to 7.4 hours after single doses and 4.5 to 12 hours with repeated dosing, prolonged in hepatic impairment and the elderly. Labeled indications (verapamil hydrochloride tablets): angina at rest and effort, rate control in atrial fibrillation or flutter with digitalis, PSVT prophylaxis, hypertension. Prescribers have ordered compounded verapamil as intralesional injections and as topical or electromotive-delivered gels for Peyronie's disease, uses reviewed by Asali and Asali, Archivio Italiano di Urologia e Andrologia 2020, who note that most studies are small and uncontrolled. Topical verapamil has also been ordered for plantar fibromatosis, where a 2018 review (Carroll et al., Foot and Ankle Specialist) notes no published efficacy study, and intralesional verapamil for keloids, where a 2022 meta-analysis (Klomparens and Simman) found it less active than intralesional triamcinolone. Dosing, strength and interval are per prescriber. Monitor blood pressure, heart rate, ECG during titration, liver enzymes, digoxin levels when coadministered, and local reactions with intralesional use. Not a controlled substance.
Swallow the capsule whole with fluid. Do not crush, chew, divide or open it, and do not dissolve it in liquid, because that can release the full dose at once. Take it at the same times each day as your label directs. Slow release forms are not meant for feeding tubes; ask your pharmacist if you need a different form.
These are nonaqueous capsules, so a USP <795> default beyond-use date of up to 180 days usually applies. Store in a closed container at room temperature, away from heat, moisture and direct light, and out of reach of children. Discard after the beyond-use date on the label.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Take 1 capsule by mouth